Correction: Pathological respiratory chemoreflex activation predicts improvement of neurocognitive function in response to comtinuous positive airway pressure (CPAP) therapy

YuTong Hu^1,2YueNan Ni^1,2*Hugi Hilmisson³Robert Joseph Thomas⁴

• ¹Department of Respiratory Care, West China School of Medicine and West China Hospital, Sichuan University, Chengdu, China
• ²Department of Respiratory, Critical Care and Sleep Medicine, West China School of Medicine and West China Hospital, Sichuan University, Chengdu, China
• ³MyCardio-LLC, Denver, United States
• ⁴Division of Pulmonary, Critical Care and Sleep Medicine, Beth Israel Deaconess Medical Center, Boston, United States

A correction refers to a change to their article that the author wishes to publish after publication. The publication of this article is subject to Frontiers' editorial approval.Instructions:• Please read through all the templates before choosing • Pick the most relevant text template(s) from the following page and delete all others.• Edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. • Please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary • Submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates. For example:There was a mistake in the Funding statement, an incorrect number was used.The correct number is "2015C03Bd051.". The publisher apologizes for this mistake.The original version of this article has been updated. Adding/removing text [an extraneous period was present after the citation " (Lv et al., 2023)."]. A correction has been made to the section [the Background section, second paragraph]: "[Continuous positive airway pressure (CPAP), which is regarded as the first line therapy for OSA, can improve hypoxia in OSA patients, reduce sleep fragmentation, and reverse sympathetic nerve excitation (Patil et al., 2019), but there is controversy regarding whether CPAP can improve cognitive dysfunction caused by OSA (Bucks et al., 2013). The existence of complex pathologies especially high loop gain maybe a reason for the failure due to impairment in both effectiveness and adherence (Ni and Thomas, 2023;Cheng et al., 2024). It is also plausible that pathological respiratory chemoreflex activation and the resulting heightened sympathetic activation and other pleotrophic effects such as oxidative stress, inflammatory response, and neuronal damage (Lv et al., 2023) may influence development of neurocognitive dysfunction, and response to treatment.]" The original version of this article has been updated. Adding/removing text [ the word "imfluences" was misspelled]. A correction has been made to the section [the Background section, fourth paragraph]:"[As described in our previous work, narrow band elevated low frequency coupling (e-LFCNB) measured by cardiopulmonary coupling sleep spectrograms is a biomarker indicating periodic breathing and central sleep apnea (Thomas et al., 2007), indicating high loop gain. Our previous study showed that e-LFCNB was a strong predictor for blood pressure dropping after CPAP in OSA (Ni et al., 2024). However, whether it influences neurocognitive function improvement by CPAP is not known.]" The original version of this article has been updated.